FDA Revokes Emergency Use of Malaria Drugs vs. Coronavirus

By Matthew Perrone

The U.S. Food and Drug Administration is revoking its emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19 amid growing evidence they don’t work and could cause deadly side effects.

The agency said Monday that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. Citing reports of heart complications, the FDA said the drugs pose a greater risk to patients than any potential benefits.

The decades-old drugs, also prescribed for lupus and rheumatoid arthritis, can cause heart rhythm problems, severely low blood pressure, and muscle or nerve damage.

The move means that shipments of the drugs obtained by the federal government will no longer be distributed to state and local health authorities. The drugs are still available for alternate uses, so U.S. doctors could still prescribe them for COVID-19 — a practice known as off-label prescribing.

On Thursday, a National Institutes of Health expert panel revised its guidelines to specifically recommend against the drug’s use except in formal studies.

Trump aggressively pushed the drug beginning in the first weeks of the outbreak and stunned medical professionals when he revealed he took the drug preemptively against infection.

More In Business

Josh D’Amaro Steps in as Disney CEO Amid Intensifying Streaming Battles

As streaming consolidation intensifies, Seth Schachner, Managing Director at StratAmericas, weighs in on Disney’s strategy under new CEO Josh D’Amaro.

Geopolitics, Trade, and Technology: The New Global Economic Order

Global markets hit a turning point as Michael Spence, Nobel Prize–winning economist and Professor Emeritus at Stanford University, assesses risks and growth.

From Check-In to Dinner: Airbnb Brings Celebrity Chefs to Your Stay

Airbnb teams up with CookUnity to deliver chef-prepared meals to rentals, blending hotel-style convenience with the comfort of cooking at home.

The Next Space Race: York Space Systems and the IPO Bet on American Orbital Power

Space investing heats up as York Space Systems CEO Dirk Wallinger discusses satellites, defense demand, and the company’s planned $4.25B IPO.

What’s it like to paint for the movies?

Isabella Watling painted portraits of characters like Benoit Blanc and his co-stars for the credits of the latest "Knives Out" movie.

Big Business This Week: Can global prosperity survive a ‘Doom Loop’?

Have we seen the end of 80 years of increasing global prosperity and relative peace?

Markets React to Fed Decision, What Happens Next?

Fed’s latest rate decision shakes markets; Nathan Sheets of Citigroup breaks down impacts on growth, inflation, labor, investor sentiment, and policy risks.

From Self-Checkout to Smart Stores: The Tech Powering Modern Retail

Jim Kelly, CEO of NCR Voyix, on how the 100-year-old company powers $1.4T in transactions and keeps reinventing retail, restaurants, and payments.

The Best and Worst Airlines of 2025: You Won’t Believe Who Came Out on Top

Allison Pohle, reporter at The Wall Street Journal, breaks down airline chaos, surprise winners, and what the latest rankings mean for your next flight.

Ducati Celebrates a Century of Racing While Gearing Up for the Future

Jason Chinnock discusses Ducati’s 100th anniversary, blending a century of racing heritage with innovation, off-road expansion, and plans for the next 100 years

Load More